长期随访来那度胺治疗套细胞淋巴瘤lenalidomide MCL课件.pdfVIP

research paper Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001 (EMERGE) pivotal trial Andre Goy,1 Sevgi Kalayoglu Besisik,2 Summary Johannes Drach,3 Radhakrishnan Ram- 4 5 Patients with mantle cell lymphoma (MCL) generally respond to first-line chandren, Michael J. Robertson, Irit Avivi,6 Jacob M. Rowe,7 Raoul Herbr- immunochemotherapy, but often